CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
December 2013—The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) and HTG Molecular Diagnostics are collaborating to begin clinical validation of a biomarker blood test that will provide early indication of organ rejection in heart transplant patients and thereby allow doctors to better monitor and treat patients post-transplant. It is the first clinical validation study of this kind in Canada.
HTG Molecular Diagnostics will implement its proprietary HTG Edge System in the clinical laboratory of St. Paul’s Hospital, Providence Health Care, Vancouver, to begin validation studies of a molecular biomarker test developed by the PROOF Centre, a not-for-profit organization focused on developing blood tests for improved health.
The HTG Edge System delivers extraction-free, multiplexed results on a multitude of biological samples in 24 hours. The fully automated platform enables the analysis of as many as 47 different genes from minimal specimen volume with walkaway simplicity, eliminating the extraction, amplification, and labeling steps normally associated with RT-PCR.
While the blood test is being validated in the clinical laboratory setting, the PROOF Centre will also work with HTG Molecular Diagnostics to prepare for its regulatory approval in North America.
PROOF Centre/a>, 604-682-2344
HTG Molecular Diagnostics, 877-289-2615